NCT07694427 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07694427
Title	Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Acronym	BEHOLD-Ovarian03
Recruitment	Not yet recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	GlaxoSmithKline
Indications	fallopian tube cancer peritoneal serous adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube transitional cell carcinoma mixed epithelial tumor of ovary endometrioid ovary carcinoma fallopian tube serous adenocarcinoma ovary transitional cell carcinoma ovarian carcinosarcoma peritoneum cancer fallopian tube clear cell adenocarcinoma ovarian serous carcinoma fallopian tube carcinosarcoma
Therapies	Bevacizumab Bevacizumab + Mocertatug rezetecan
Age Groups:	senior \| adult
Covered Countries	ARG

Facility	Status	City	State	Zip	Country	Details
GSK Investigational Site		Ciudad Autonoma de Buenos Aire		C1426AGE	Argentina	Details
GSK Investigational Site		Niigata		951-8520	Japan	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07694427Clinical Trial Detail